AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02271178 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Combined capsule
Description: Combined capsule containing ramipril (5 to 10 mg), atenolol (50 to 100 mg), 100 mg aspirin, 40 mg simvastatin. In follow-up visits doses of atenolol and ramipril capsules may be adjusted according to blood pressure and heart rate.
Study NCT01057589 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Triplet Combination Therapy: 500 mg/m\^2 administered intravenously on Day 1 of 21 day cycle for up to 6 cycles~Maintenance Therapy: 500mg/m\^2 administered intravenously on Day 1 of 21 day cycle until disease progression or unacceptable toxicity
Study NCT01057589 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Triplet Combination Therapy: 400 mg/m\^2 administered intravenously on Day 1 of 21 day cycle for 1 cycle; 250 mg/m\^2 administered IV infusion on Day 1 of 21 day cycle and then weekly for up to 6 cycles.~Maintenance Therapy: 250 mg/m\^2 administered intravenously on Day 1 of 21 day cycle and then weekly until disease progression or unacceptable toxicity
Study NCT01057589 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Triplet Combination Therapy: 75mg/m\^2 administered intravenously on Day 1 of 21 day cycle for up to 6 cycles.
Study NCT02271178 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Conventional therapy
Description: Usual therapy
Study NCT03871413 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TRV-chair
Description: Repositioning maneuvers in TRV-chair
Study NCT01057589 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Folic Acid
Description: Standard of care dietary supplements: 350 to 1000 µg orally 5 times a day for the 7 days preceding the first dose of first dose of pemetrexed and continuing throughout treatment and for 21 days after the last dose of pemetrexed.
Study NCT01057589 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin B12
Description: Standard of care dietary supplements: 1000 µg IM during the week preceding the first dose of pemetrexed and every 9 weeks thereafter.
Study NCT02712047 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone furoate (FF) (100 mcg)
Description: First blister strip contains FF blended with lactose, 100 mcg per blister
Study NCT02712047 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vilanterol (VI) (25 mcg)
Description: Second blister strip contains vilanterol blended with lactose and magnesium stearate, 25 mcg per blister
Study NCT02712047 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo will have two blister strips, identical in appearance to the inhaler containing active study medication; one containing lactose and the second strip containing lactose and magnesium stearate
Study NCT03697915 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Experimental
Description: Conventional physical therapy was administered to the control group and was aimed at achieving sitting balance in the first phase; once sitting balance could be achieved, we aimed at achieving standing balance in the second phase. Once standing balance was also achieved, supported and unsupported ambulation was commenced in the final phase.
Study NCT03697915 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Experimental
Description: Conventional physical therapy was administered to the control group and was aimed at achieving sitting balance in the first phase; once sitting balance could be achieved, we aimed at achieving standing balance in the second phase. Once standing balance was also achieved, supported and unsupported ambulation was commenced in the final phase.
Study NCT03871413 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Manual repositioning maneuver
Description: Treatment with manual repositioning maneuver
Study NCT03197727 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: GC Saliva-Check BUFFER
Description: Evaluating the saliva flow rate, saliva pH and saliva buffering capacity
Study NCT00128843 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Exemestane
Description: 25mg/day until progression disease
Study NCT00128843 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anastrozole
Description: 1mg/day until progression disease
Study NCT04587765 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Extra-curricular sports
Description: The group follows the schedule of school teaching programme. Extra-curricular sports classes will be organized and provided in this group of schools in the afternoon after school until 6 p.m. (Monday to Friday).
Study NCT03111186 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxycodone Hcl 5Mg
Description: oxycodone HCl 5 mg up to six times daily as needed for pain
Study NCT03111186 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen 400 mg
Description: Ibuprofen 400 mg up to six times daily as needed for pain
Study NCT03111186 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen 650 mg
Description: Acetaminophen 650 mg up to four times daily as needed for pain
Study NCT03171181 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vestibular reeducation
Description: Balance quality was registered with static and dynamic posturography. For spatial orientation is was registered Visual vertical and visual orientation perception. Vestibular disability was also assessed. Variables were registered at the beginning and at the end of a vestibular rehabilitation in UPVD participants. Vestibular rehabilitation consisted of 10 sessions of vestibular rehabilitation using dynamic posturography and visual reeducation. Duration of each session: 40 minutes. Twice a week.
Study NCT05170932 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CHX gel 2 % + 24% EDTA
Description: The local drug delivery gel (24% of EDTA gel on root and bone surface and then application of 2% of chlorhexidine gel on root surface) were placed for group 2 in the periodontal pockets Filter paper were inserted into the orifice of the pocket for 1 minute. This was done in the day of surgery then after 3 days, 7 days, 14 days and 21 days after the local drug delivery to measure the gel release profile.
Study NCT01516034 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cupola Tattoo Removal device
Description: Up to 6 treatments with the device every 2-3 weeks to the tattoo area.
Study NCT03849625 — intervention group
Intervention type: DRUG
Intervention: aspirin, NSAIDs, paracetamol
Description: Perform skin test and/or provocation test with aspirin, paracetmol, or suspected NSAIDs in questionable cases
Study NCT04340271 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Extracorporeal shock wave therapy
Description: ESWT was conducted using the Duolith SD-1® device (StorzMedical, Tägerwilen, Switzerland) with an electromagnetic cylindrical coil source for the focused shock wave (Fig. 2). ESWT was performed around the primary treatment site at 100 impulses/cm2, an energy flux density(EFD) of 0.05 to 0.30 mJ/mm2, frequency of 4Hz, and 1000 to 2000 impulses were administered at 1-week intervals for 4 sessions.
Study NCT04340271 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: conventional occupational therapy
Description: Standard accupational therapy consist of range of motion exercise, strengthening exercises, and activities of daily living exercises
Study NCT04340271 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: conventional occupational therapy
Description: Standard accupational therapy consist of range of motion exercise, strengthening exercises, and activities of daily living exercises
Study NCT01818752 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Description: Carfilzomib was administered over 30 minutes on days 1, 2, 8, 9, 22, 23, 29, and 30 for nine 42-day cycles. Carfilzomib 20 mg/m² IV was administered on days 1 and 2 of cycle 1, followed by escalation to 36 mg/m² IV starting on day 8 of cycle 1.
Study NCT01818752 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bortezomib
Description: Bortezomib 1.3 mg/m² was administered as a bolus IV injection or as a subcutaneous injection (per investigator's choice, dose modification, or regulatory approval) on days 1, 4, 8, 11, 22, 25, 29, and 32 of cycles 1 to 4, and on days 1, 8, 22, and 29 of cycles 5 to 9.
Study NCT01818752 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Melphalan
Description: Melphalan 9 mg/m² was taken orally on days 1 to 4 of all cycles.
Study NCT01818752 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: Melphalan 9 mg/m² was taken orally on days 1 to 4 of all cycles.
Study NCT03600350 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pTVG-HP
Description: Plasmid DNA vaccine encoding Prostatic Acid Phosphatase (PAP)
Study NCT03600350 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab is a human programmed death receptor-1 (PD-1)-blocking antibody indicated for the treatment of patients with multiple different types of cancer.
Study NCT01818752 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: Prednisone 60 mg/m² was taken orally on days 1 to 4 of all cycles.
Study NCT01818752 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Prednisone 60 mg/m² was taken orally on days 1 to 4 of all cycles.
Study NCT03600350 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GM-CSF
Description: Granulocyte-macrophage colony-stimulating factor (GM-CSF) is a growth factor that supports the survival, clonal expansion and differentiation of hematopoietic progenitor cells including dendritic antigen presenting cells.
Study NCT00541814 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclosporine
Description: Target drug level 50-100 ng/ml or cyclosporine withdrawal
Study NCT00541814 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine
Description: Target drug level 50-100 ng/ml or cyclosporine withdrawal
Study NCT01924416 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced Care (intervention group and comparison group)
Description: Decision aid coupled with immediate QL-PRO results
Study NCT01924416 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual care (routine chemotherapy cycles and imaging studies)
Description: Usual care does not receive intervention
Study NCT02057081 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multifamily Group for mTBI for Couples
Description: MFG-mTBI-C uses a structured problem-solving and skills training approach to provide Veterans and partners with tools and information to improve coping and help couples reconnect through positive behavioral exchanges.
Study NCT02234271 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mobile Health Application
Description: Mobile Health application for contraception information
Study NCT02234271 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Health Educator Counseling
Description: Counseling via health educator
Study NCT01176929 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual treatment and Prevention program
Description: Prevention program of recurrent suicidal acts includes three interventions:~* A series of three telephone calls ( the second week , one month and three months after discharge from hospital )~* A systematic telephone contact with the referring physician~* A telephone helpline for people who made a suicide attempt and referring physicians.
Study NCT01176929 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Treatment
Description: Usual Treatment
Study NCT02253342 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WCK-2349
Description: Each subject will receive ten oral doses of 1000 mg WCK 2349 administered twice-daily starting on Day 1
Study NCT02057081 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Group Health Education (GHE)
Description: GHE is a 14-session, highly structured educational intervention providing general information on health problems that are common among the general OEF/OIF cohort including sleep and sleep problems, physical activity and exercise, and alcohol and drug use, as well as guidelines for improving health behavior in these areas.
Study NCT00580671 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: MET/CBT
Description: Weekly Individual Counseling Sessions
Study NCT00580671 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MET/CBT
Description: Weekly Individual Counseling Sessions
Study NCT00580671 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CM
Description: Abstinence-based incentives delivered contingent on drug-negative urine test results.
Study NCT03317496 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab 800 mg in combination with pemetrexed / carboplatin
Description: Avelumab Pemetrexed Carboplatin
Study NCT03317496 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab 800 mg in combination with gemcitabine / cisplatin.
Description: Avelumab Gemcitabine Cisplatin
Study NCT03317496 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab 1200 mg in combination with pemetrexed/carboplatin
Description: Avelumab Pemetrexed Carboplatin
Study NCT03317496 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab 1200 mg in combination with gemcitabine/cisplatin
Description: Avelumab Gemcitabine Cisplatin
Study NCT04011072 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Far infrared radiation
Description: The treatment group will receive FIR for 40 minutes on the skin above the fistula during each dialysis session for one year.
Study NCT02587416 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcabene 300 mg
Description: 1x300 mg gemcabene tablets orally once daily (QD) for 11 days
Study NCT02587416 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcabene 900 mg
Description: 3x300 mg Gemcabene tablets orally once daily (QD) for 11 days
Study NCT02587416 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin
Description: 2x40 mg Atorvastatin tablets orally once daily (QD)
Study NCT02587416 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: 2x40 mg Atorvastatin tablets orally once daily (QD)
Study NCT03834168 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: standardized Study Diet
Description: Standardized diet consisted with eucaloric meals with 4.5 gm of sodium per day for 5 days.
Study NCT00316004 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 7.5% Hypertonic Saline in 6% Dextran-70 (HSD)
Description: 250 ml intravenous bolus administration of 7.5% saline/6% dextran 70 administered as a one-time bolus fluid for initial resuscitation to injured patients with suspected severe traumatic brain injury in the out-of-hospital setting.
Study NCT00316004 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 7.5% Hypertonic Saline (HS)
Description: 250 ml intravenous bolus administration of 7.5% hypertonic saline administered as a one-time bolus fluid for initial resuscitation to injured patients with suspected severe traumatic brain injury in the out-of-hospital setting.
Study NCT00316004 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% Normal Saline (NS)
Description: 250 ml intravenous bolus administration of 0.9% saline administered as a one-time bolus fluid for initial resuscitation to injured patients with suspected severe traumatic brain injury in the out-of-hospital setting.
Study NCT01134042 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone Furoate/Vilanterol Inhalation Powder
Description: Fluticasone furoate/Vilanterol inhalation powder inhaled orally once daily for 24 weeks
Study NCT01134042 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone Furoate Inhalation Powder
Description: Fluticasone furoate inhalation powder inhaled orally once daily for 24 weeks
Study NCT01134042 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone Propionate Inhalation Powder
Description: Fluticasone propionate inhalation powder inhaled orally twice daily for 24 weeks
Study NCT01134042 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Inhalation Powder 1
Description: Placebo in novel dry powder inhaler once daily
Study NCT01134042 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Inhalation Powder 2
Description: Placebo in Diskus inhaler twice daily
Study NCT01134042 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo Inhalation Powder 2
Description: Placebo in Diskus inhaler twice daily
Study NCT03434262 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Given intravenously (IV).
Study NCT03434262 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ribociclib
Description: Given orally (PO).
Study NCT03434262 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sonidegib
Description: Given PO.
Study NCT03434262 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: trametinib
Description: Given PO.
Study NCT03434262 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: Given subcutaneously (SQ).
Study NCT00580671 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BPT
Description: Behavioral parent training involve 14 weekly counseling curriculum to improve parenting skills.
Study NCT02467426 — intervention group
Intervention type: DRUG
Intervention: Chemotherapy
Description: intraarterial infusion of cisplatin and mithoxantrone
Study NCT00967980 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Femoral Nerve Block vs. Psoas Compartment Nerve Block
Description: Patients, undergoing hip arthroplasty or hip resurfacing will be randomized to one of two groups: femoral nerve block or psoas compartment nerve block. Patients randomized to femoral nerve block will receive this block prior to surgery. Patients randomized to psoas compartment nerve block will receive this block prior to surgery. Both patients will receive Mepivicaine via catheter prior to surgery and following surgery, Ropivicaine via pain pump.
Study NCT03723967 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab with Carboplatin/Paclitaxel
Description: Durvalumab associated with Carboplatin / Paclitaxel as first line treatment in patients with recurrent/metastatic SCCHN not eligible to standard chemotherapy
Study NCT03248791 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Phenylephrine
Description: Phenylephrine variable infusion with a starting rate of 0.75 mcg/Kg/min.
Study NCT03248791 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Norepinephrine
Description: Norepinephrine variable infusion with a starting rate of 0.1 mcg/Kg/min.
Study NCT03248791 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: Bupivacaine will be injected in the subarachnoid space with a dose of 10 mg
Study NCT03248791 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: Bupivacaine will be injected in the subarachnoid space with a dose of 10 mg
Study NCT03586570 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aprocitentan 25mg
Description: Oral tablets in strength of 25 mg
Study NCT03586570 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral tablets matching aprocitentan tablets
Study NCT04516954 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Convalescent COVID 19 Plasma
Description: A total of 500 ml of convalescent COVID 19 plasma will be transfused intravenously per subject
Study NCT03113097 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Embryo transfer
Description: Transfer of different qualities of embryos at blastocyst stage
Study NCT02972567 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lactobacillus spp
Description: 9 log10 cfu/capsule. 1 capsule/day for 12 weeks
Study NCT02972567 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Maltodextrin
Study NCT03510741 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium Benzoate
Description: Sodium Benzoate will be administered at 1000mg daily
Study NCT03510741 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: N-Acetylcysteine
Description: N-Acetylcysteine 1000 mgs twice daily dose
Study NCT03510741 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo added to TAU
Study NCT02471183 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selexipag
Description: Tablets for oral administration containing 200 micrograms (mcg) of selexipag to be administered twice a day. The individual dose is to be established during the first 12 weeks of the study. Doses are in the range from 200 micrograms (1 tablet) to 1,600 micrograms (8 tablets).
Study NCT03510741 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium Benzoate Plus N-Acetylcysteine
Description: Sodium Benzoate will be administered at 1000mg daily and NAC 1000 mgs twice daily dose
Study NCT04007354 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ventilation method
Description: Depending on the group assignment, mechanical ventilation or spontaneous breathing was performed.